Top

Published in:

01-06-2010 | PRECLINICAL STUDIES

Screening of a PKC ζ-specific kinase inhibitor PKCzI257.3 which inhibits EGF-induced breast cancer cell chemotaxis

Authors: Jing Wu, Baogang Zhang, Min Wu, Hongyan Li, Ruifang Niu, Guoguang Ying, Ning Zhang

Published in: Investigational New Drugs | Issue 3/2010

Summary

Chemotaxis has recently been implicated in tumor metastasis. Protein Kinase C(PKC)ζ is often over-activated and is a key signal transducer shared by both EGFR- and CXCR4-mediated chemotactic signaling in human breast and lung cancers, as well as CSF-1-induced macrophage migration. In order to develop potential inhibitors targeting PKCζ for effective blockage of cancer cell chemotaxis and tumor metastasis, the Z′-LYTE™ KINASE ASSAY -SER/THR 7 PEPTIDE Kit was used and a compound called PKCzI257.3 was identified with IC50 of 28 µM. As a result of treatment, chemotactic migration potency of the human breast cancer cell MDA-MB-231 were impaired, while no significant effect was observed on cell proliferation. Furthermore, EGF-induced cofilin phosphorylation, a critical step of cofilin recycle and actin polymerization, was also dampened, which was relevant to the decreased cell migration. Our results suggest that PKCzI257.3 is a PKCζ-specific compound inhibitor which blocked cancer cell migration and may serve as a potential therapeutic drug for cancer treatment.

Fidler IJ (2002) Critical determinants of metastasis. Semin Cancer Biol 12:89–96. doi:10.1006/scbi.2001.0416 CrossRefPubMed

Ben Baruch A (2008) Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 25:345–356. doi:10.1007/s10585-007-9097-3 CrossRefPubMed

Payne AS, Cornelius LA (2002) The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 118:915–922. doi:10.1046/j.1523-1747.2002.01725.x CrossRefPubMed

Comer FI, Parent CA (2002) PI 3-kinases and PTEN: how opposites chemoattract. Cell 109:541–544. doi:10.1016/S0092-8674(02)00765-1 CrossRefPubMed

Deshpande DA, Pascual RM, Wang SW, Eckman DM, Riemer EC, Funk CD, Penn RB (2007) PKC-dependent regulation of the receptor locus dominates functional consequences of cysteinyl leukotriene type 1 receptor activation. FASEB J 21:2335–2342. doi:10.1096/fj.06-8060com CrossRefPubMed

Kuehn HS, Gilfillan AM (2007) G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation. Immunol Lett 113:59–69. doi:10.1016/j.imlet.2007.08.007 CrossRefPubMed

Sun R, Gao P, Chen L, Ma D, Wang J, Oppenheim JJ, Zhang N (2005) Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. Cancer Res 65:1433–1441. doi:10.1158/0008-5472.CAN-04-1163 CrossRefPubMed

Paolucci L, Rozengurt E (1999) Protein kinase D in small cell lung cancer cells: rapid activation through protein kinase C. Cancer Res 59:572–577PubMed

Zugaza JL, Sinnett-Smith J, Van Lint J, Rozengurt E (1996) Protein kinase D (PKD) activation in intact cells through a protein kinase C-dependent signal transduction pathway. EMBO J 15:6220–6230PubMed

10.

Nishizuka Y (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607–614. doi:10.1126/science.1411571 CrossRefPubMed

11.

Moscat J, Rennert P, Diaz-Meco MT (2006) PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways. Cell Death Differ 13:702–711. doi:10.1038/sj.cdd.4401823 CrossRefPubMed

12.

Rabinovitz I, Toker A, Mercurio AM (1999) Protein kinase C-dependent mobilization of the alpha6beta4 integrin from hemidesmosomes and its association with actin-rich cell protrusions drive the chemotactic migration of carcinoma cells. J Cell Biol 146:1147–1160. doi:10.1083/jcb.146.5.1147 CrossRefPubMed

13.

Parsons M, Keppler MD, Kline A, Messent A, Humphries MJ, Gilchrist R, Hart IR, Quittau-Prevostel C, Hughes WE, Parker PJ, Ng T (2002) Site-directed perturbation of protein kinase C- integrin interaction blocks carcinoma cell chemotaxis. Mol Cell Biol 22:5897–5911. doi:10.1128/MCB.22.16.5897-5911.2002 CrossRefPubMed

14.

Kruger JS, Reddy KB (2003) Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol Cancer Res 1:801–809PubMed

15.

Iwabu A, Smith K, Allen FD, Lauffenburger DA, Wells A (2004) Epidermal growth factor induces fibroblast contractility and motility via a protein kinase C delta-dependent pathway. J Biol Chem 279:14551–14560. doi:10.1074/jbc.M311981200 CrossRefPubMed

16.

Etienne-Manneville S, Hall A (2001) Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCzeta. Cell 106:489–498. doi:10.1016/S0092-8674(01)00471-8 CrossRefPubMed

17.

Etienne-Manneville S, Hall A (2003) Cdc42 regulates GSK-3beta and adenomatous polyposis coli to control cell polarity. Nature 421:753–756. doi:10.1038/nature01423 CrossRefPubMed

18.

Hirai T, Chida K (2003) Protein kinase Czeta (PKCzeta): activation mechanisms and cellular functions. J Biochem 133:1–7. doi:10.1093/jb/mvg017 CrossRefPubMed

19.

Joberty G, Petersen C, Gao L, Macara IG (2000) The cell-polarity protein Par6 links Par3 and atypical protein kinase C to Cdc42. Nat Cell Biol 2:531–539. doi:10.1038/35019573 CrossRefPubMed

20.

Lin D, Edwards AS, Fawcett JP, Mbamalu G, Scott JD, Pawson T (2000) A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity. Nat Cell Biol 2:540–547. doi:10.1038/35019592 CrossRefPubMed

21.

Giagulli C, Scarpini E, Ottoboni L, Narumiya S, Butcher EC, Constantin G, Laudanna C (2004) RhoA and zeta PKC control distinct modalities of LFA-1 activation by chemokines: critical role of LFA-1 affinity triggering in lymphocyte in vivo homing. Immunity 20:25–35. doi:10.1016/S1074-7613(03)00350-9 CrossRefPubMed

22.

Laudanna C, Mochly-Rosen D, Liron T, Constantin G, Butcher EC (1998) Evidence of zeta protein kinase C involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis. J Biol Chem 273:30306–30315. doi:10.1074/jbc.273.46.30306 CrossRefPubMed

23.

Liu Y, Wang B, Wang J, Wan W, Sun R, Zhao Y, Zhang N (2009) Down-regulation of PKCzeta expression inhibits chemotaxis signal transduction in human lung cancer cells. Lung Cancer 63:210–218. doi:10.1016/j.lungcan.2008.05.010 CrossRefPubMed

24.

Guo H, Ma Y, Zhang B, Sun B, Niu R, Ying G, Zhang N (2009) Pivotal Advance: PKC{zeta} is required for migration of macrophages. J Leukoc Biol

25.

Rodems SM, Hamman BD, Lin C, Zhao J, Shah S, Heidary D, Makings L, Stack JH, Pollok BA (2002) A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. Assay Drug Dev Technol 1:9–19. doi:10.1089/154065802761001266 CrossRefPubMed

26.

Doerr ME, Jones JI (1996) The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 271:2443–2447. doi:10.1074/jbc.271.5.2443 CrossRefPubMed

27.

Zigmond SH, Joyce M, Borleis J, Bokoch GM, Devreotes PN (1997) Regulation of actin polymerization in cell-free systems by GTPgammaS and Cdc42. J Cell Biol 138:363–374. doi:10.1083/jcb.138.2.363 CrossRefPubMed

28.

Ghosh M, Song X, Mouneimne G, Sidani M, Lawrence DS, Condeelis JS (2004) Cofilin promotes actin polymerization and defines the direction of cell motility. Science 304:743–746. doi:10.1126/science.1094561 CrossRefPubMed

29.

Sharkey NA, Leach KL, Blumberg PM (1984) Competitive inhibition by diacylglycerol of specific phorbol ester binding. Proc Natl Acad Sci USA 81:607–610. doi:10.1073/pnas.81.2.607 CrossRefPubMed

30.

Podar K, Raab MS, Chauhan D, Anderson KC (2007) The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs 16:1693–1707. doi:10.1517/13543784.16.10.1693 CrossRefPubMed

Title: Screening of a PKC ζ-specific kinase inhibitor PKCzI257.3 which inhibits EGF-induced breast cancer cell chemotaxis
Authors: Jing Wu
Baogang Zhang
Min Wu
Hongyan Li
Ruifang Niu
Guoguang Ying
Ning Zhang
Publication date: 01-06-2010
Publisher: Springer US
Published in: Investigational New Drugs / Issue 3/2010
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-009-9242-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 3/2010

Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent

Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response

MMPT: a thiazolidin compound inhibits the growth of lung cancer H1792 cells via Fas-mediated and caspase-dependent apoptosis pathway

Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience

Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo

Possible contribution of β-glycosidases and caspases in the cytotoxicity of novel glycoconjugates in colon cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer